NCT04461457View on ClinicalTrials.gov

Targeted Radiation Therapy for Ovarian Cancer: Intraperitoneal Treatment With 211-astatine-MX35 F(ab')2

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

February 5, 2005

Primary Completion Date

March 19, 2011

Study Completion Date

January 19, 2012

Conditions
Ovarian Cancer
Interventions
COMBINATION_PRODUCT

211-astatine MX35 F(ab')2

Alpha emitting radionuclide 211At conjugated to monoclonal antibody MX35 F(ab')2. Targeting the sodium phosphate transporter (NaPi2b).

Trial Locations (1)

41345

Sahlgrenska University Hospital, Dept of Oncology, Gothenburg

All Listed Sponsors
collaborator

Swedish Cancer Society

OTHER

collaborator

The Swedish Research Council

OTHER_GOV

collaborator

Sahlgrenska University Hospital

OTHER

lead

Vastra Gotaland Region

OTHER_GOV

NCT04461457 - Targeted Radiation Therapy for Ovarian Cancer: Intraperitoneal Treatment With 211-astatine-MX35 F(ab')2 | Biotech Hunter | Biotech Hunter